Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.

Polesso F, Sarker M, Weinberg AD, Murray SE, Moran AE.

J Immunol. 2019 Aug 21. pii: ji1900696. doi: 10.4049/jimmunol.1900696. [Epub ahead of print]

PMID:
31434709
2.

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.

Hoffmann PR, Hoffmann FW, Premeaux TA, Fujita T, Soprana E, Panigada M, Chew GM, Richard G, Hindocha P, Menor M, Khadka VS, Deng Y, Moise L, Ndhlovu LC, Siccardi A, Weinberg AD, De Groot AS, Bertino P.

Front Oncol. 2019 Aug 2;9:720. doi: 10.3389/fonc.2019.00720. eCollection 2019.

3.

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.

Polesso F, Weinberg AD, Moran AE.

Cancer Immunol Res. 2019 Feb;7(2):269-281. doi: 10.1158/2326-6066.CIR-18-0222. Epub 2018 Dec 18.

PMID:
30563828
4.

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.

Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD.

Nat Commun. 2018 Jul 13;9(1):2724. doi: 10.1038/s41467-018-05072-0.

5.

Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].

Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12. No abstract available.

PMID:
28202215
6.

Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.

Yu G, Li Y, Cui Z, Morris NP, Weinberg AD, Fox BA, Urba WJ, Wang L, Hu HM.

Sci Rep. 2016 Nov 22;6:37558. doi: 10.1038/srep37558.

7.

Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.

Bryan RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2016 Oct;61:166-76. doi: 10.1016/j.oraloncology.2016.08.020. Epub 2016 Sep 7. Review. Erratum in: Oral Oncol. 2017 Mar;66:e3.

PMID:
27614589
8.

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

Moran AE, Polesso F, Weinberg AD.

J Immunol. 2016 Sep 15;197(6):2509-21. doi: 10.4049/jimmunol.1502659. Epub 2016 Aug 8.

9.

Blood Pool Segmentation Results in Superior Virtual Cardiac Models than Myocardial Segmentation for 3D Printing.

Farooqi KM, Lengua CG, Weinberg AD, Nielsen JC, Sanz J.

Pediatr Cardiol. 2016 Aug;37(6):1028-36. doi: 10.1007/s00246-016-1385-8. Epub 2016 Apr 4.

PMID:
27041098
10.

Simulation as a set-up for technical proficiency: can a virtual warm-up improve live fibre-optic intubation?

Samuelson ST, Burnett G, Sim AJ, Hofer I, Weinberg AD, Goldberg A, Chang TS, DeMaria S Jr.

Br J Anaesth. 2016 Mar;116(3):398-404. doi: 10.1093/bja/aev436. Epub 2016 Jan 27.

11.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
12.

Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: A survey of U.S. transplantation centers.

Gin GE, Pereira JF, Weinberg AD, Mehrazin R, Lerner SM, Sfakianos JP, Phillips CK.

Urol Oncol. 2016 Feb;34(2):57.e9-13. doi: 10.1016/j.urolonc.2015.08.020. Epub 2015 Oct 1.

PMID:
26433443
13.

High-resolution microendoscope imaging of inverted papilloma and normal sinonasal mucosa: evaluation of interobserver concordance.

Parasher AK, Kidwai SM, Schorn VJ, Goljo E, Weinberg AD, Richards-Kortum R, Sikora AG, Iloreta AM, Govindaraj S, Miles BA.

Int Forum Allergy Rhinol. 2015 Dec;5(12):1136-40. doi: 10.1002/alr.21603. Epub 2015 Jul 30.

PMID:
26228817
14.

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.

Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD.

Cancer Immunol Res. 2015 May;3(5):526-35. doi: 10.1158/2326-6066.CIR-14-0187. Epub 2015 Jan 27.

15.

Developing NaviCanPlan: A Mobile Web Resource Locator for Cancer Providers and Survivors.

Vollmer Dahlke D, Kellstedt D, Weinberg AD.

J Cancer Educ. 2015 Dec;30(4):670-6. doi: 10.1007/s13187-014-0768-x.

PMID:
25519250
16.

Positive perceptions on safety and satisfaction during a patient-centered timeout before peripheral nerve blockade.

Lai YH, Anderson MR, Weinberg AD, Rosenblatt MA.

J Clin Anesth. 2015 May;27(3):214-20. doi: 10.1016/j.jclinane.2014.10.009. Epub 2014 Dec 12.

PMID:
25499270
17.

Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities.

Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Tucker CG, Montler R, Haley D, Newell P, Ma J, Tseng P, Wolf R, Vetto JT, Hammill C, Hansen P, Weinberg AD.

J Immunother Cancer. 2014 Nov 18;2(1):38. doi: 10.1186/s40425-014-0038-9. eCollection 2014.

18.

Ambulatory spine surgery: a survey study.

Baird EO, Brietzke SC, Weinberg AD, McAnany SJ, Qureshi SA, Cho SK, Hecht AC.

Global Spine J. 2014 Aug;4(3):157-60. doi: 10.1055/s-0034-1378142. Epub 2014 Jun 9.

19.

Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell priming.

Farazi M, Cohn Z, Nguyen J, Weinberg AD, Ruby CE.

J Leukoc Biol. 2014 Aug;96(2):245-54. doi: 10.1189/jlb.1A0114-066R. Epub 2014 Apr 8.

PMID:
24714553
20.

Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging.

Farazi M, Nguyen J, Goldufsky J, Linnane S, Lukaesko L, Weinberg AD, Ruby CE.

Cancer Immunol Immunother. 2014 Jun;63(6):615-26. doi: 10.1007/s00262-014-1542-y. Epub 2014 Mar 30.

21.

OX40 is a potent immune-stimulating target in late-stage cancer patients.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD.

Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31.

22.

Occurrence of steam pops during irrigated RF ablation: novel insights from microwave radiometry.

Koruth JS, Dukkipati S, Gangireddy S, McCarthy J, Spencer D, Weinberg AD, Miller MA, D'Avila A, Reddy VY.

J Cardiovasc Electrophysiol. 2013 Nov;24(11):1271-7. doi: 10.1111/jce.12181. Epub 2013 Jun 10.

PMID:
23751084
23.

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Moran AE, Kovacsovics-Bankowski M, Weinberg AD.

Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Review.

24.

Prospective, multicenter study of ventricular assist device infections.

Gordon RJ, Weinberg AD, Pagani FD, Slaughter MS, Pappas PS, Naka Y, Goldstein DJ, Dembitsky WP, Giacalone JC, Ferrante J, Ascheim DD, Moskowitz AJ, Rose EA, Gelijns AC, Lowy FD; Ventricular Assist Device Infection Study Group.

Circulation. 2013 Feb 12;127(6):691-702. doi: 10.1161/CIRCULATIONAHA.112.128132. Epub 2013 Jan 11.

25.

Adjuvant chemotherapy for stage III colon cancer in the oldest old: results beyond clinical guidelines.

Abraham A, Habermann EB, Rothenberger DA, Kwaan M, Weinberg AD, Parsons HM, Gupta P, Al-Refaie WB.

Cancer. 2013 Jan 15;119(2):395-403. doi: 10.1002/cncr.27755. Epub 2012 Jul 17.

26.

Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG.

Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD.

Eur J Immunol. 2012 Jul;42(7):1893-905. doi: 10.1002/eji.201242444.

27.

Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.

Gough MJ, Killeen N, Weinberg AD.

Immunology. 2012 Aug;136(4):437-47. doi: 10.1111/j.1365-2567.2012.03600.x.

28.

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Redmond WL, Triplett T, Floyd K, Weinberg AD.

PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4.

29.

Staphylococcus epidermidis colonization is highly clonal across US cardiac centers.

Gordon RJ, Miragaia M, Weinberg AD, Lee CJ, Rolo J, Giacalone JC, Slaughter MS, Pappas P, Naka Y, Tector AJ, de Lencastre H, Lowy FD.

J Infect Dis. 2012 May 1;205(9):1391-8. doi: 10.1093/infdis/jis218. Epub 2012 Mar 29.

30.

Science gone translational: the OX40 agonist story.

Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD.

Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Review.

31.

The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.

Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD, Akporiaye ET.

Cancer Immunol Immunother. 2012 Apr;61(4):511-21. doi: 10.1007/s00262-011-1119-y. Epub 2011 Oct 5.

32.

OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.

Vasilevsky NA, Ruby CE, Hurlin PJ, Weinberg AD.

Eur J Immunol. 2011 Apr;41(4):1024-34. doi: 10.1002/eji.201040449. Epub 2011 Mar 14.

33.

A survey of environmental safety issues at 20 medical clinics.

Savely SM, Hamilton WJ, Degani F, Weinberg AD, Muraca P.

J Environ Health. 2011 Jan-Feb;73(6):86-94.

PMID:
21306100
34.

Genetic testing and cancer risk management recommendations by physicians for at-risk relatives.

Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck S.

Genet Med. 2011 Feb;13(2):148-54. doi: 10.1097/GIM.0b013e318207f564.

35.

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA.

Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Review.

36.

Progress in addressing disparities through comprehensive cancer control.

Weinberg AD, Jackson PM, DeCourtney CA, Cravatt K, Ogo J, Sanchez MM, Tortolero-Luna G, Rollins RL.

Cancer Causes Control. 2010 Dec;21(12):2015-21. doi: 10.1007/s10552-010-9649-8. Epub 2010 Nov 5. Review.

PMID:
21057869
37.

OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis.

Karulf M, Kelly A, Weinberg AD, Gold JA.

J Immunol. 2010 Oct 15;185(8):4856-62. doi: 10.4049/jimmunol.1000404. Epub 2010 Sep 15.

38.

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD.

J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095.

39.

Optimized temporary biventricular pacing acutely improves intraoperative cardiac output after weaning from cardiopulmonary bypass: a substudy of a randomized clinical trial.

Wang DY, Richmond ME, Quinn TA, Mirani AJ, Rusanov A, Yalamanchi V, Weinberg AD, Cabreriza SE, Spotnitz HM.

J Thorac Cardiovasc Surg. 2011 Apr;141(4):1002-8, 1008.e1. doi: 10.1016/j.jtcvs.2010.07.004. Epub 2010 Aug 30.

40.

The role of OX40 (CD134) in T-cell memory generation.

Weinberg AD.

Adv Exp Med Biol. 2010;684:57-68.

PMID:
20795540
41.

Relation of QRS shortening to cardiac output during temporary resynchronization therapy after cardiac surgery.

Spotnitz ME, Richmond ME, Quinn TA, Cabreriza SE, Wang DY, Albright CM, Weinberg AD, Dizon JM, Spotnitz HM.

ASAIO J. 2010 Sep-Oct;56(5):434-40. doi: 10.1097/MAT.0b013e3181e88ac6.

42.

Feasibility of in vivo pressure measurement using a pressure-tip catheter via transventricular puncture.

Gray RG, Cabreriza SE, Quinn TA, Weinberg AD, Spotnitz HM.

ASAIO J. 2010 May-Jun;56(3):194-9. doi: 10.1097/MAT.0b013e3181d823a1.

43.

Validation of automated monitoring of cardiac output for biventricular pacing optimization.

George EM, Cabreriza SE, Quinn TA, Rusanov A, Gerrah R, Broyles JM, Weinberg AD, Spotnitz HM.

ASAIO J. 2010 May-Jun;56(3):265-9. doi: 10.1097/MAT.0b013e3181cf882a.

44.

Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change.

Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD.

Am J Public Health. 2010 Apr 1;100 Suppl 1:S105-12. doi: 10.2105/AJPH.2009.162982. Epub 2010 Feb 10.

45.

Implementing recommendations to eliminate disparities in clinical trial research.

Evans GL, Weinberg AD.

J Cancer Educ. 2009;24(2 Suppl):S50-1. doi: 10.1080/08858190903400518. No abstract available.

PMID:
20024826
46.

Policies to address disparities in clinical trials: the EDICT Project.

Spiker CA, Weinberg AD.

J Cancer Educ. 2009;24(2 Suppl):S39-49. doi: 10.1080/08858190903400500. No abstract available.

PMID:
20024825
47.

Simultaneous variation of ventricular pacing site and timing with biventricular pacing in acute ventricular failure improves function by interventricular assist.

Quinn TA, Cabreriza SE, Richmond ME, Weinberg AD, Holmes JW, Spotnitz HM.

Am J Physiol Heart Circ Physiol. 2009 Dec;297(6):H2220-6. doi: 10.1152/ajpheart.00802.2009. Epub 2009 Oct 23.

48.

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD.

J Immunol. 2009 Oct 15;183(8):4853-7. doi: 10.4049/jimmunol.0901112. Epub 2009 Sep 28.

49.

Cardiac output measurement by arterial pressure waveform analysis during optimization of biventricular pacing after cardiac surgery.

Booth JH, Quinn TA, Richmond ME, Cabreriza SE, Weinberg AD, Johnston T, Spotnitz HM.

ASAIO J. 2009 Nov-Dec;55(6):587-91. doi: 10.1097/MAT.0b013e3181bbafd5.

50.

OX40 (CD134) and OX40L.

Gough MJ, Weinberg AD.

Adv Exp Med Biol. 2009;647:94-107. doi: 10.1007/978-0-387-89520-8_6. Review.

PMID:
19760068

Supplemental Content

Loading ...
Support Center